BVS - Bioventus - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BVS is currently covered by 3 analysts with an average price target of $10.99. This is a potential upside of $3.78 (52.43%) from yesterday's end of day stock price of $7.21.

Bioventus's activity chart (see below) currently has 24 price targets and 29 ratings on display. The stock rating distribution of BVS is 87.5% BUY and 12.5% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 34.72% with an average time for these price targets to be met of 191.5 days.

Highest price target for BVS is $15, Lowest price target is $13, average price target is $14.

Most recent stock forecast was given by ROBBIE MARCUS from JPMORGAN on 17-Dec-2024. First documented stock forecast 08-Mar-2021.

Currently out of the existing stock ratings of BVS, 7 are a BUY (87.5%), 1 are a HOLD (12.5%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$13

$5.63 (76.39%)

8 months 3 days ago
(17-Dec-2024)

1/3 (33.33%)

$1.85 (16.59%)

79

Buy

$15

$7.63 (103.53%)

$12

9 months 14 days ago
(06-Nov-2024)

3/4 (75%)

$3.72 (32.98%)

124

Hold

$6

$2.7 (81.82%)

2 years 11 days ago
(09-Aug-2023)

0/2 (0%)

$9.08 (82.36%)

Hold

$2.5

$-4.87 (-66.08%)

$13

2 years 8 months 21 days ago
(30-Nov-2022)

2/4 (50%)

$0.55 (28.21%)

393

Buy

$6

$-4.54 (-43.07%)

$23

2 years 9 months 11 days ago
(09-Nov-2022)

1/2 (50%)

$3.42 (132.56%)

553

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BVS (Bioventus) average time for price targets to be met?

On average it took 191.5 days on average for the stock forecasts to be realized with a an average price target met ratio 34.72

Which analyst has the current highest performing score on BVS (Bioventus) with a proven track record?

AMIT HAZAN

Which analyst has the current lower performing score on BVS (Bioventus) with a proven track record?

ALEXANDER NOWAK

Which analyst has the most public recommendations on BVS (Bioventus)?

Amit Hazan has 8 price targets and 10 ratings on BVS

Which analyst is the currently most bullish on BVS (Bioventus)?

Drew Ranieri with highest potential upside - $8.81

Which analyst is the currently most reserved on BVS (Bioventus)?

Amit Hazan with lowest potential downside - -$4.87

Bioventus in the News

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live...

Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance

Earnings Call Insights: Bioventus Inc. (BVS) Q2 2025 MANAGEMENT VIEW * Robert E. Claypoole, President and CEO, highlighted, “Second quarter revenue of $148 million was in line with our expectations and reflected the strength of our portfolio’s diversity as we drove above-market organic growth of 6% even with challenging prior year comparisons in pain treatments.”...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?